Suppr超能文献

胃肠道中的阿片受体:功能性肠病中治疗腹泻和便秘的靶点?

Opioid receptors in the GI tract: targets for treatment of both diarrhea and constipation in functional bowel disorders?

机构信息

Catholic University of Leuven, KU Leuven, Translational Research Center for Gastrointestinal Disorders (TARGID), Leuven, Belgium.

NIHR Nottingham Biomedical Research Centre (BRC), Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, UK; Nottingham Digestive Diseases Centre, School of Medicine, University of Nottingham, Nottingham, UK.

出版信息

Curr Opin Pharmacol. 2018 Dec;43:53-58. doi: 10.1016/j.coph.2018.08.008. Epub 2018 Sep 3.

Abstract

Opioids have been used for centuries, mostly as a sedative and to treat pain. Currently, they are used on a global scale for the treatment of acute and chronic pain in diseases as osteoarthritis, fibromyalgia, and low back pain. Binding of opioids on opioid receptors can cause a range of different effects such as changes in stress response, analgesia, motor activity and autonomic functions. This review provide a synthetic summary of the most recent literature on the use of drugs acting on mu-receptors to treat two prevalent functional bowel disorders, presenting with opposite bowel habit. Eluxadoline and naloxegol, methylnaltrexone and naldemedine are recently FDA and/or EMA approved drugs demonstrated to be effective and safe for treatment respectively of irritable bowel syndrome subtype diarrhea and opioid induced constipation.

摘要

阿片类药物已经使用了几个世纪,主要用作镇静剂和治疗疼痛。目前,它们在全球范围内被用于治疗骨关节炎、纤维肌痛和腰痛等疾病的急性和慢性疼痛。阿片类药物与阿片受体的结合会引起一系列不同的效果,如应激反应、镇痛、运动活动和自主功能的改变。这篇综述综合了最近关于使用作用于μ-受体的药物治疗两种常见功能性肠病的文献,这两种疾病表现出相反的肠习惯。Eluxadoline 和 naloxegol、methylnaltrexone 和 naldemedine 是最近获得美国食品药品监督管理局和/或欧洲药品管理局批准的药物,分别被证明对治疗肠易激综合征腹泻型和阿片类药物引起的便秘有效且安全。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验